Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression

被引：40

作者：

Hoogewerf, M ^{[1
]}

Regez, RM ^{[1
]}

Schouten, WEM ^{[1
]}

Weigel, HM ^{[1
]}

Frissen, PHJ ^{[1
]}

Brinkman, K ^{[1
]}

机构：

[1] Onze Lieve Vrouw Hosp, Dept Internal Med, Amsterdam, Netherlands

来源：

LANCET | 2003年 / 362卷 / 9400期

关键词：

D O I：

10.1016/S0140-6736(03)15018-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients who have not received previous antiretroviral treatment (ART) have a high failure rate on the combination treatment of abacavir, lamivudine, and tenovir. We assessed the virological failure rate in eight patients with HIV-1 who switched to this combination after having complete virological suppression from their previous long-term ART (median 8.0 months, range 7.5-18.0). Five of the eight patients showed virological failure. Four of these five patients had either the K65R mutation, the M184V/l mutation, or both. This combination of drugs cannot therefore be recommended as alternative treatment in patients with HIV-1 who are fully virologically suppressed.

引用

页码：1979 / 1980

页数：2

共 7 条

[1] Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA [J].

Clumeck, N ;

Goebel, F ;

Rozenbaum, W ;

Gerstoft, J ;

Staszewski, S ;

Montaner, J ;

Johnson, M ;

Gazzard, B ;

Stone, C ;

Athisegaran, R ;

Moore, S .

AIDS, 2001, 15 (12) :1517-1526

[2]

FARTHING C, 2003, 2 INT AIDS SOC IAS P

[3] Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [J].

Finzi, D ;

Hermankova, M ;

Pierson, T ;

Carruth, LM ;

Buck, C ;

Chaisson, RE ;

Quinn, TC ;

Chadwick, K ;

Margolick, J ;

Brookmeyer, R ;

Gallant, J ;

Markowitz, M ;

Ho, DD ;

Richman, DD ;

Siliciano, RF .

SCIENCE, 1997, 278 (5341) :1295-1300

[4]

GALLANT J, 2003, 43 INT C MICR AG CHE

[5]

Katlama C, 2003, HIV Med, V4, P79, DOI 10.1046/j.1468-1293.2003.00139.x

[6] Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection [J].

Martinez, E ;

Arnaiz, JA ;

Podzamczer, D ;

Dalmau, D ;

Ribera, E ;

Domingo, P ;

Knobel, H ;

Riera, M ;

Pedrol, E ;

Force, L ;

Llibre, JM ;

Segura, F ;

Richart, C ;

Cortes, C ;

Javaloyas, M ;

Aranda, M ;

Cruceta, A ;

de Lazzari, E ;

Gatell, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (11) :1036-1046

[7]

PILIERO P, 2003, 43 INT C MICR AG CHE

← 1 →